Gustave Roussy and AstraZeneca form joint oncology research alliance

5 June 2014

The France-based Gustave Roussy comprehensive cancer center and Anglo-Swedish drug major AstraZeneca (LSE: AZN) have entered into a joint strategic alliance focussed on early oncology drug development. The partners will develop a joint strategic collaboration plan that will be overseen by a joint steering committee.

As part of this strategic alliance, AstraZeneca will make its entire portfolio of innovative oncology molecules for preclinical, translational and early clinical studies available to Gustave Roussy, with the goal of targeting molecular aberrations that drive individual cancers via the modulation of critical cellular signalling pathways and deepening our understanding of how the patient's immune system interacts with cancer. The alliance will involve several parallel and inter-connected projects that will span preclinical, translational and clinical phases of drug development.

Latest collaboration adds to previous work together

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK